|Bid||2.2600 x 0|
|Ask||2.2900 x 0|
|Day's Range||2.2700 - 2.3000|
|52 Week Range||1.1600 - 2.6600|
|Beta (3Y Monthly)||-0.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 26, 2019 - Aug 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.88|
NYSE | TSX : ACB Broader Lending Syndicate Introduced to Fund Strategic Growth Initiatives EDMONTON , Aug. 15, 2019 /CNW/ - Aurora Cannabis Inc. ("Aurora or the "Company") (NYSE | TSX: ACB), ...
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) reports today that it has been added to The Cannabis ETF (NYSE:THCX) (“THCX”) which trades on the New York Stock Exchange. THCX follows the Innovation Labs Cannabis Index, which is a portfolio of 35 holdings expected to benefit from growth of the legal marijuana, CBD and hemp industries. EnWave currently has three royalty-bearing commercial license agreements with Canadian cannabis companies and one royalty-bearing commercial license agreement with a hemp producer in the United States.
EDMONTON, Aug. 6, 2019 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, today provided a corporate update on selected financial metrics for the fourth quarter of the Company's Fiscal 2019 ("Q4 2019") period ended June 30, 2019. This reiteration of guidance and clarification of operations is intended to update our investors as Aurora continues to demonstrate leadership in transparency and disclosure as the industry navigates throughs periods of volatility. Based on a preliminary (unaudited) review, the Company anticipates net revenues for the quarter ended June 30, 2019 of between $100 million and $107 million (net of excise taxes), compared to $19.1 million in the period ended June 30, 2018, and compared to $65.1 million for the previous quarter ended March 31, 2019. Fiscal Q4 2019 net cannabis revenue is expected to be between $90 million and $95 million, with growth anticipated across all key business segments including medical, both Canadian and international, and consumer markets. The Company anticipates total net revenues for the fiscal year ended June 30, 2019 to be between $249 million - $256 million.
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) reports today that the Company has received a non-refundable USD$100,000 deposit from Consulting Fresh Business S.L. (“Fresh Business”) towards the purchase of Radiant Energy Vacuum (“REV™”) machinery with a minimum of 100kW in rated power. In April 2019, Fresh Business purchased a small-scale commercial REV™ machine and signed an exclusive license to use EnWave’s REV™ technology in the country of Peru for the dehydration of numerous food materials.
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) reports today that it has signed a royalty-bearing commercial license agreement (the "License") with Electric Farms LLC (“Electric Farms”). Electric Farms cultivates high-quality hemp flowers in both indoor and outdoor grow facilities at its licensed facility in Tennessee, USA.
New studies to advance the science on CBD use and athlete health and wellness and to drive product development under new U.S. sports performance brand, ROAR Sports TSX: ACB | NYSE: ACB LAS VEGAS , July ...
Secures Two-Year Contract to Continue to Supply Italy with high-quality medical cannabis NYSE: ACB TSX:ACB EDMONTON , July 18, 2019 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") ...
New Outdoor research sites in Quebec and British Columbia to study best-in-class cultivation techniques and advance plant science NYSE: ACB TSX:ACB EDMONTON , July 15, 2019 /CNW/ - Aurora Cannabis Inc. ...
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) reports today that Aurora Cannabis Inc. (“Aurora”) (ACB.TO) (ACB), is expanding the scope of requirements for its potential purchase of a third 120kW Radiant Energy Vacuum (“REV™”) machine targeted for its European operations in Denmark. Aurora Nordic Cannabis, a subsidiary of Aurora, plans to develop a pharmaceutical-level GMP facility, which requires several upgrades to the contemplated machinery. These upgrades will be confirmed as soon as possible and will also increase the economic profile of this prospective equipment purchase. On April 26, 2019, EnWave and Aurora announced that the companies had entered into a royalty-bearing commercial license agreement with sub-licensing rights, providing Aurora with the exclusive rights to EnWave’s patented REV™ drying technology for the production of cannabis materials in the European Union, excluding Portugal (the “European License”).
EDMONTON, June 21, 2019 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE:ACB - News) (TSX:ACB - News), the Canadian company defining the future of cannabis worldwide, today announced its plans for the highly-anticipated expansion of the consumer cannabis market into vapes, concentrates, and edibles. Through a combination of new and enhanced facilities, Aurora intends to produce new, high-quality products across the country in a variety of product categories. Aurora recently entered into a supply agreement with PAX Labs Inc., a leading consumer technology brand in cannabis.